ACIU vs MMTZF
AC Immune SA and MindMaze Therapeutics Holding SA, side by side — 3 fiscal years reported in CHF, drawn from SEC filings.
Most recent reported year
| Metric | ACIU | MMTZF |
|---|---|---|
| Revenue | CHF 3.6M | CHF 6.3M |
| Net income | CHF -70.4M | CHF -98.2M |
| Gross margin | · | · |
| Net margin | · | · |
| Return on equity | −89.7% | −99.4% |
| Diluted EPS | −CHF 0.70 | −CHF 8.35 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | CHF -70.2M | CHF -18.1M |
| Equity | · | · |
| Net debt / equity | · | · |
| Current ratio | 1.02× | 2.65× |
| Revenue CAGR 5y | · | · |
| Profit CAGR 5y | · | · |
MMTZF bills 1.8× the revenue of ACIU, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
3 years side by side
| Fiscal year | ACIU | MMTZF |
|---|---|---|
| FY2023 | CHF 14.8M | CHF 6.3M |
| FY2022 | CHF 3.9M | CHF 7.1M |
| FY2021 | CHF 0 | CHF 4.5M |
Bottom line
| Fiscal year | ACIU | MMTZF |
|---|---|---|
| FY2023 | CHF -54.2M | CHF -98.2M |
| FY2022 | CHF -70.8M | CHF -50.8M |
| FY2021 | CHF -73.0M | CHF -34.7M |
Standard deviation, each side
MMTZF's return on equity has been more volatile than ACIU's over the 3 comparable fiscal years — 35.3 percentage points of standard deviation against 1.2.
3 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ACIU and MMTZF over these 3 fiscal years — ACIU led in 1 and MMTZF in 2.
3 of 11 comparable fiscal years — a year missing data on either side is not counted.